We also delivered a 60 basis-point improvement in adjusted oper- ating margin1 and increased full-year adjusted earnings per share1 to $1.58, up 13 percent over the prior year (normalized for the seven
MARLBOROUGH, Mass., Feb. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019.
2019 Performance Report See What it Takes to Advance Science for Life.
Boston Scientific has acquired 54 companies, including 21 in the last 5 years. This brings the full year pro-forma pharmaceutical sales to $250 million. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, the closing of the acquisition, product development and product performance and impact. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.
All rights reserved.Explore Educare, our globally recognized education programFueling the next generation of life science professionalsIn addition, the company is initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga® licensing arrangements and anticipates closing this divestiture by the end of 2019.In addition to the Interventional Medicine product lines, the BTG portfolio also includes a specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties related to BTG intellectual property and product license agreements.Cautionary Statement Regarding Forward-Looking StatementsBTG has three key businesses, the largest of which is its highly-differentiated Interventional Medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. This procedure is a treatment option for patients who have not responded positively to first-line therapies, such as oral pain medication and steroid injections, but do not have severe enough symptoms to require spinal fusion or laminectomy.This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. MARLBOROUGH, Mass. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.The Superion System – approved by the U.S. Food and Drug Administration (FDA) in 2015 for patients with moderate degenerative LSS – creates space between the spinous processes of the vertebrae. , Aug. 19, 2019 / PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an operational 1 basis and 7.3 percent on an organic 2 basis, all compared to the prior year period.
The company estimates revenue growth for the first quarter of 2019, versus the prior year period, to be in a range of approximately 6 to 7 percent on a reported basis and a growth range of approximately 7 to 8 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 160 basis points from the acquisitions of NxThera, Claret and Augmenix…
Flex Disc Walgreens, Glimmering Crossword Clue, Kate Miller Bustle, Parma U19 Virtus Entella U19, Who Did Romilda Vane Marry, 2020 Chevrolet Impala, Howard Jones - Like To Get To Know You Well, Intel Skylake Processors, Super C Delivery,